Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 28, 2007

Lundbeck’s Value Drops after Halt of Insomnia Drug Development with Merck & Co.

  • Merck & Co. and H. Lundbeck are suspending Phase III trials of their insomnia drug. The companies report that data from recently completed clinical studies suggests that the overall clinical profile for gaboxadol in insomnia does not support further development.

    Phase II trials of the drug were marked by side effects, such as tachycardia, headache, nausea, vomiting and fatigue.

    In morning trading, while Merck’s stock price decreased by less than 1%, Lundbeck’s value took a beating. The company’s shares slid over 16% to Kr. 26.50, or $4.75, from it closing price of Kr. 159.50, or $28.59.

    "The termination of our joint insomnia development program with Lundbeck is clearly disappointing," remarks Peter S. Kim, Ph.D., president of Merck Research Laboratories. Merck asserts that they will continue research in this area and are open to collaborating with Lundbeck.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »